Abstract
Accumulation of 5-aminolevulinic acid (ALA) is the main defect in acute porphyria and the most likely potential candidate to cause acute neurological manifestations during an acute porphyric attack via multiple direct and indirect mechanisms. ALA is a potential endogenous source of reactive oxygen species (ROS). After administration of ALA or inducers of ALA-synthase in in vitro conditions or in animal models, the main pro-oxidants detected have been superoxide, hydrogen peroxide, hydroxyl radicals, and 4,5-dioxovaleric acid (DOVA), which has produced oxidative damage (OD) to lipids, proteins, and DNA. At the organelle level, ALA-induced OD affects the permeability of the biological membranes, probably as a result of protein polymerization and lipid peroxidation. In vitro exposure to ALA has caused OD to Schwann cells and inhibited myelin formation. Magnetic resonance imaging (MRI) of patients with acute intermittent porphyria (AIP) who suffer from severe reversible posterior encephalopathy syndrome (PRES) during the acute attack shows features of impaired permeability of the blood–brain barrier (BBB); this could be the result of oxidative stress (OS) allowing neurotoxins such as ALA to damage neurons. Peripheral demyelination found in heterozygote or homozygote patients with AIP could be caused by direct OD caused by ALA, which produces pro-oxidants that may affect Schwann cells and myelin. Because ALA is not the most potent pro-oxidant, the OD is only a minor contributor to the neurological manifestations of AIP in general. It could, however, explain the fact that encephalopathy and peripheral demyelination are present only during severe attacks of AIP, in which the high level of serum ALA results in significant auto-oxidation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AIP:
-
Acute intermittent porphyria
- ALA:
-
5-Aminolevulinic acid
- ALAS:
-
ALA synthase
- BBB:
-
Blood–brain barrier
- CNS:
-
Central nervous system
- CSF:
-
Cerebrospinal fluid
- DHPY:
-
3,6-Dihydropyrazine-2,5-dipropanoic acid
- DOVA:
-
4,5-Dioxovaleric acid
- GABA:
-
Gamma amino butyric acid
- HCP:
-
Hereditary coproporphyria
- HMBS:
-
Hydroxymethylbilane synthase
- MRI:
-
Magnetic resonance imaging
- OD:
-
Oxidative damage
- OS:
-
Oxidative stress
- PBG:
-
Porphobilinogen
- PNP:
-
Peripheral neuropathy, polyneuropathy
- ROS:
-
Reactive oxygen species
- SIADH:
-
Syndrome of inadequate secretion of antidiuretic hormone
- VP:
-
Variegate porphyria
References
Kauppinen R. Porphyrias. Lancet. 2005;365:241–52.
Pischik E, Kauppinen R. Neurological manifestations of acute intermittent porphyria. Cell Mol Biol (Noisy-le-grand). 2009;55:72–83.
Meyer UA, Schuurmans MM, Lindberg RL. Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis. 1998;18:43–52.
Kauppinen R, von und zu Fraunberg M. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem. 2002;48:1891–900.
Poh-Fitzpatrick MB. Molecular and cellular mechanisms of porphyrin photosensitization. Photodermatology. 1986;3:148–57.
von und zu Fraunberg M, Timonen K, Mustajoki P, et al. Clinical and biochemical characteristics and genotype–phenotype correlation in Finnish variegate porphyria patients. Eur J Hum Genet. 2002;10:649–57.
Bechara EJ, Dutra F, Cardoso VE, et al. The dual face of endogenous alpha-aminoketones: pro-oxidizing metabolic weapons. Comp Biochem Physiol C Toxicol Pharmacol. 2007;146:88–110.
Strand LJ, Felsher BF, Redeker AG, et al. Heme biosynthesis in intermittent acute prophyria: decreased hepatic conversion of porphobilinogen to porphyrins and increased delta aminolevulinic acid synthetase activity. Proc Natl Acad Sci U S A. 1970;67:1315–20.
Meyer UA, Strand LJ, Doss M, et al. Intermittent acute porphyria – demonstration of genetic defect in porphobilinogen metabolism. N Engl J Med. 1972;286:1277–82.
Sassa S, Solish G, Levere RD, et al. Studies in porphyria. IV. Expression of the gene defect of acute intermittent porphyria in cultured human skin fibroblasts and amniotic cells: prenatal diagnosis of the porphyric trait. J Exp Med. 1975;142:722–31.
Sassa S, Zalar GL, Kappas A. Studies in porphyria. VII. Induction of uroporphyrinogen-I synthase and expression of the gene defect of acute intermittent porphyria in mitogen-stimulated human lymphocytes. J Clin Invest. 1978;61:499–508.
Fraser DJ, Podvinec M, Kaufmann MR, et al. Drugs mediate the transcriptional activation of the 5-aminolevulinic acid synthase (ALAS1) gene via the chicken xenobiotic-sensing nuclear receptor (CXR). J Biol Chem. 2002;277:34717–26.
Handschin C, Lin J, Rhee J, et al. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell. 2005;122:505–15.
Rodgers PA, Stevenson DK. Developmental biology of heme oxygenase. Clin Perinatol. 1990;17:275–91.
Hift RJ, Meissner PN. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine (Baltim). 2005;84:48–60.
Mustajoki P, Nordmann Y. Early administration of heme arginate for acute porphyric attacks. Arch Intern Med. 1993;153:2004–8.
Jover R, Hoffmann F, Scheffler-Koch V, et al. Limited heme synthesis in porphobilinogen deaminase-deficient mice impairs transcriptional activation of specific cytochrome P450 genes by phenobarbital. Eur J Biochem. 2000;267:7128–37.
Loots JM, Becker DM, Meyer BJ, et al. The effect of porphyrin precursors on monosynaptic reflex activity in the isolated hemisected frog spinal cord. J Neural Transm. 1975;36:71–81.
Percy VA, Lamm MCTaljaard JJDelta-aminolaevulinic acid uptake, toxicity, and effect on [14C]gamma-aminobutyric acid uptake into neurons and glia in culture. J Neurochem. 1981;36:69–76.
Cutler MG, Mair J, Moore MR. Pharmacological activities of delta-aminolaevulinic acid, protoporphyrin IX and haemin in isolated preparations of rabbit gastric fundus and jejunum J Auton Pharmacol. 1990;10:119–26.
Sardh E, Harper P, Andersson DE, et al. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks. Eur J Intern Med. 2009;20:201–7.
Mustajoki P, Timonen K, Gorchein A, et al. Sustained high plasma 5-aminolevulinic acid concentration in a volunteer: no porphyric symptoms. Eur J Clin Invest. 1992;22:407–11.
Fukuda H, Casas A, Batlle A. Aminolevulinic acid: from its unique biological function to its star role in photodynamic therapy. Int J Biochem Cell Biol. 2005;37:272–6.
Adhikari A, Penatti CA, Resende RR, et al. 5-Aminolevulinate and 4,5-dioxovalerate ions decrease GABA(A) receptor density in neuronal cells, synaptosomes and rat brain. Brain Res. 2006;1093:95–104.
Brennan MJ, Cantrill RC. Delta-aminolaevulinic acid and amino acid neurotransmitters. Mol Cell Biochem. 1981;38:49–58.
Princ FG, Juknat AA, Amitrano AA, et al. Effect of reactive oxygen species promoted by delta-aminolevulinic acid on porphyrin biosynthesis and glucose uptake in rat cerebellum. Gen Pharmacol. 1998;31:143–8.
Oteiza PI, Bechara EJ. 5-Aminolevulinic acid induces lipid peroxidation in cardiolipin-rich liposomes. Arch Biochem Biophys. 1993;305:282–7.
Vercesi AE, Castilho RF, Meinicke AR, et al. Oxidative damage of mitochondria induced by 5-aminolevulinic acid: role of Ca2+ and membrane protein thiols. Biochim Biophys Acta. 1994;1188:86–92.
Fraga CG, Onuki J, Lucesoli F, et al. 5-Aminolevulinic acid mediates the in vivo and in vitro formation of 8-hydroxy-2′-deoxyguanosine in DNA. Carcinogenesis (Oxf). 1994;15:2241–4.
Felitsyn N, McLeod C, Shroads AL, et al. The heme precursor delta-aminolevulinate blocks peripheral myelin formation. J Neurochem. 2008;106:2068–79.
Hunter GA, Rivera E, Ferreira GC. Supraphysiological concentrations of 5-aminolevulinic acid dimerize in solution to produce superoxide radical anions via a protonated dihydropyrazine intermediate. Arch Biochem Biophys. 2005;437:128–37.
Onuki J, Rech CM, Medeiros MH, et al. Genotoxicity of 5-aminolevulinic and 4,5-dioxovaleric acids in the Salmonella/microsuspension mutagenicity assay and SOS chromotest. Environ Mol Mutagen. 2002;40:63–70.
Velosa AC, Baader WJ, Stevani CV, et al. 1,3-Diene probes for detection of triplet carbonyls in biological systems. Chem Res Toxicol. 2007;20:1162–9.
Lee JC, Son YO, Choi KC, et al. Hydrogen peroxide induces apoptosis of BJAB cells due to formation of hydroxyl radicals via intracellular iron-mediated Fenton chemistry in glucose oxidase-mediated oxidative stress. Mol Cells. 2006;22:21–9.
Timmins GS, Liu KJ, Bechara EJ, et al. Trapping of free radicals with direct in vivo EPR detection: a comparison of 5,5-dimethyl-1-pyrroline-N-oxide and 5-diethoxyphosphoryl-5-methyl-1-pyrroline-N-oxide as spin traps for HO* and SO4*. Free Radic Biol Med. 1999;27:329–33.
Ummus RE, Onuki J, Dornemann D, et al. Measurement of 4,5-dioxovaleric acid by high-performance liquid chromatography and fluorescence detection. J Chromatogr B Biomed Sci Appl. 1999;729:237–43.
Lelli SM, San Martin de Viale LC, Mazzetti MB. Response of glucose metabolism enzymes in an acute porphyria model. Role of reactive oxygen species. Toxicology. 2005;216:49–58.
Rodriguez JA, Martinez Mdel C, Gerez E, et al. Heme oxygenase, aminolevulinate acid synthetase and the antioxidant system in the brain of mice treated with porphyrinogenic drugs. Cell Mol Biol (Noisy-le-grand). 2005;51:487–94.
Cheeseman KH, Slater TF. An introduction to free radical biochemistry. Br Med Bull. 1993;49:481–93.
Piao ZH, Yoon SR, Kim MS, et al. VDUP1 potentiates Ras-mediated angiogenesis via ROS production in endothelial cells. Cell Mol Biol (Noisy-le-grand). 2009;55:1096–103.
Calabrese V, Lodi R, Tonon C, et al. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich’s ataxia. J Neurol Sci. 2005;233:145–62.
Mitra S, Abraham E. Participation of superoxide in neutrophil activation and cytokine production. Biochim Biophys Acta. 2006;1762:732–41.
Demasi M, Penatti CA, DeLuca R, et al. The prooxidant effect of 5-aminolevulinic acid in the brain tissue of rats: implication in neuropsychiatric manifestation in porphyrias. Free Radic Biol Med. 1996;20:291–9.
Rocha ME, Dutra F, Bandy B, et al. Oxidative damage to ferritin by 5-aminolevulinic acid. Arch Biochem Biophys. 2003;409:349–56.
Hermes-Lima M, Castilho RF, Valle VG, et al. Calcium-dependent mitochondrial oxidative damage promoted by 5-aminolevulinic acid. Biochim Biophys Acta. 1992;1180:201–6.
Rocha ME, Bandy B, Costa CA, et al. Iron mobilization by succinylacetone methyl ester in rats. A model study for hereditary tyrosinemia and porphyrias characterized by 5-aminolevulinic acid overload. Free Radic Res. 2000;32:343–53.
Monteiro HP, Abdalla DS, Augusto O, et al. Free radical generation during d-aminolevulinic acid autooxidaation: induction by hemoglobin and connections with porphyrinopathies. Arch Biochem Biophys. 1989;271:206–16.
Mattson MP. Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders. Ann N Y Acad Sci. 2004;1012:37–50.
Hermes-Lima M. How do Ca2+ and 5-aminolevulinic acid-derived oxyradicals promote injury to isolated mitochondria? Free Radic Biol Med. 1995;19:381–90.
Douki T, Onuki J, Medeiros MH, et al. DNA alkylation by 4,5-dioxovaleric acid, the final oxidation product of 5-aminolevulinic acid. Chem Res Toxicol. 1998;11:150–7.
Penatti CA, Bechara EJ, Demasi M. Delta-aminolevulinic acid-induced synaptosomal Ca2+ uptake and mitochondrial permeabilization. Arch Biochem Biophys. 1996;335:53–60.
Medeiros MH, Marchiori PE, Bechara EJ. Superoxide dismutase, glutathione peroxidase, and catalase activities in the erythrocytes of patients with intermittent acute porphyria. Clin Chem. 1982;28:242–3.
Ferrer MD, Tauler P, Sureda A, et al. Enzyme antioxidant defences and oxidative damage in red blood cells of variegate porphyria patients. Redox Rep. 2009;14:69–74.
Brown SB. The role of light in the treatment of non-melanoma skin cancer using methyl aminolevulinate. J Dermatol Treat. 2003;14 (suppl 3):11–4.
Friesen SA, Hjortland GO, Madsen SJ, et al. 5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors (review). Int J Oncol. 2002;21:577–82.
Frank J, Lambert C, Biesalski HK, et al. Intensified oxidative and nitrosative stress following combined ALA-based photodynamic therapy and local hyperthermia in rat tumors. Int J Cancer. 2003;107:941–8.
Wahlin S, Srikanthan N, Hamre B, et al. Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria. Liver Transplant. 2008;14:1340–6.
von und zu Fraunberg M, Pischik E, Udd L, et al. Clinical and biochemical characteristics and genotype-phenotype correlation in 143 Finnish and Russian patients with acute intermittent porphyria. Medicine (Baltim). 2005;84:35–47.
Pischik E, Bulyanitsa A, Kazakov V, et al. Clinical features predictive of a poor prognosis in acute porphyria [letter]. J Neurol. 2004;251:1538–41.
Percy VA, Shanley BC. Porphyrin precursors in blood, urine and cerebrospinal fluid in acute porphyria. South Afr Med J. 1977;52:219.
Gorchein A, Webber R. d-Aminolaevulinic acid in plasma, cerebrospinal fluid, saliva and erythrocytes: studies in normal, uraemic and porphyric subjects. Clin Sci. 1987;72:103–12.
King PH, Bragdon AC MRI reveals multiple reversible cerebral lesions in an attack of acute intermittent porphyria. Neurology. 1991;41:1300–2.
Aggarwal A, Quint DJ, Lynch JP. MR imaging of porphyric encephalopathy. Am J Roentgenol. 1994;162:1218–20.
Kupferschmidt H, Bont A, Schnorf H, et al. Transient cortical blindness and bioccipital brain lesions in two patients with acute intermittent porphyria. Ann Intern Med. 1995;123:598–600.
Black KS, Mirsky P, Kalina P, et al. Angiographic demonstration of reversible cerebral vasospasm in porphyric encephalopathy. Am J Neuroradiol. 1995;16:1650–2.
Susa S, Daimon M, Morita Y, et al. Acute intermittent porphyria with central pontine myelinolysis and cortical laminar necrosis. Neuroradiology. 1999;41:835–9.
Garg MK, Mohaparto AK, Dugal JS, et al. Cortical blindness in acute intermittent porphyria. J Assoc Physicians India. 1999;47:727–9.
Utz N, Kinkel B, Hedde JP, et al. MR imaging of acute intermittent porphyria mimicking reversible posterior leukoencephalopathy syndrome. Neuroradiology. 2001;43:1059–62.
Yen PS, Chen CJ, Lui CC, et al. Diffusion-weighted magnetic resonance imaging of porphyric encephalopathy: a case report. Eur Neurol. 2002;48:119–21.
Celik M, Forta H, Dalkilic T, et al. MRI reveals reversible lesions resembling posterior reversible encephalopathy in porphyria. Neuroradiology. 2002;44:839–41.
Engelhardt K, Trinka E, Franz G, et al. Refractory status epilepticus due to acute hepatic porphyria in a pregnant woman: induced abortion as the sole therapeutic option? Eur J Neurol. 2004;11:693–7.
Maramattom BV, Zaldivar RA, Glynn SM, et al. Acute intermittent porphyria presenting as a diffuse encephalopathy. Ann Neurol. 2005;57:581–4.
Wessels T, Blaes F, Rottger C, et al. Cortical amaurosis and status epilepticus with acute porphyria. Nervenarzt. 2005;76:992–5, 7–8.
Neal CR, Hunter AJ, Harper SJ, et al. Plasma from women with severe pre-eclampsia increases microvascular permeability in an animal model in vivo. Clin Sci (Lond). 2004;107:399–405.
Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol. 1999;9:69–92.
Pop-Busui R, Sima A, Stevens M. Diabetic neuropathy and oxidative stress. Diabetes Metab Res Rev. 2006;22:257–73.
Ridley A. The neuropathy of acute intermittent porphyria. Q J Med. 1969;38:307–33.
Albers JW, Robertson WC, Daube JR. Electrodiagnostic findings in acute porphyric neuropathy. Muscle Nerve. 1978;1:292–6.
Barohn RJ, Sanchez JA, Anderson KE. Acute peripheral neuropathy due to hereditary coproporphyria. Muscle Nerve. 1994;17:793–9.
Defanti CA, Sghirlanzoni A, Bottacchi E, et al. Porphyric neuropathy: a clinical, neurophysiological and morphological study. Ital J Neurol Sci. 1985;6:521–6.
Flugel KA, Druschky K-F. Electromyogram and nerve conduction in patients with acute intermittent porphyria. J Neurol. 1977;214:265–79.
King PH, Petersen NE, Rakhra R, et al. Porphyria presenting with bilateral radial motor neuropathy: evidence of a novel gene mutation. Neurology. 2002;58:1118–21.
Maytham DV, Eales L. Electrodiagnostic findings in porphyria. J Lab Clin Med. 1971;17:99–100.
Nagler W. Peripheral neuropathy in acute intermittent porphyrias. Arch Phys Med Rehabil. 1971;52:426–31.
Reichenmiller HE, Zysno EA. Neuropsychiatrische Strörungen bei vier Fällen von akuter intermittierender Porphyrie. Verhandl Dtsch Gesellsch Med. 1970:748–52.
Stein JA, Tschudy DP. Acute intermittent porphyria: a clinical and biochemical study of 46 patients. Medicine (Baltim). 1970;49:1–16.
Wochnik-Dyjas D, Niewiadomska M, Kostrzewska E. Porphyric polyneuropathy and its pathogenesis in the light of electrophysiological investigations. J Neurol Sci. 1978;35:243–56.
Zimmerman EA, Lovelace R. The etiology of the neuropathy in acute intermittent porphyria. Trans Am Neurol Assoc. 1968;93:294–6.
Kasper LD, Braunwald E, Fauci A, et al. Harrison’s principles of internal medicine. 16th ed. New York: McGraw-Hill; 2005.
Denny-Brown D, Sciarra D. Changes in the nervous system in acute porphyria. Brain. 1945;68:1–16.
Gibson JB, Goldberg A. The neuropathology of acute porphyria. J Pathol Bacteriol. 1956;71:495–506.
Hierons R. Changes in the nervous system in acute porphyria. Brain. 1957;80:176–92.
Anzil AP, Dozhic S. Peripheral nerve changes in porphyric neuropathy: findings in sural nerve biopsy. Acta Neuropathol. 1978;42:121–6.
Suarez JI, Cohen ML, Larkin J, et al. Acute intermittent porphyria: clinicopathological correlation. Report of a case and review of the literature. Neurology. 1997;48:1678–83.
Pischik E. Neurological manifestations and molecular genetics of acute intermittent porphyria in North Western Russia. Helsinki: University of Helsinki; 2006.
Solis C, Martinez-Bermejo A, Naidich TP, et al. Acute intermittent porphyria: studies of the severe homozygous dominant disease provides insights into the neurologic attacks in acute porphyrias. Arch Neurol. 2004;61:1764–70.
Juknat AA, Kotler ML, Quaglino A, et al. Necrotic cell death induced by delta-aminolevulinic acid in mouse astrocytes. Protective role of melatonin and other antioxidants. J Pineal Res. 2003;35:1–11.
Karbownik M, Reiter RJ. Melatonin protects against oxidative stress caused by delta-aminolevulinic acid: implications for cancer reduction. Cancer Invest. 2002;20:276–86.
Noriega GO, Tomaro ML, del Batlle AM. Bilirubin is highly effective in preventing in vivo delta-aminolevulinic acid-induced oxidative cell damage. Biochim Biophys Acta. 2003;1638:173–8.
Huang WC, Juang SW, Liu IM, et al. Changes of superoxide dismutase gene expression and activity in the brain of streptozotocin-induced diabetic rats. Neurosci Lett. 1999;275:28–5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Pischik, E., Kauppinen, R. (2011). Potential Role of Oxidative Damage in Neurological Manifestations of Acute Intermittent Porphyria. In: Gadoth, N., Göbel, H. (eds) Oxidative Stress and Free Radical Damage in Neurology. Oxidative Stress in Applied Basic Research and Clinical Practice. Humana Press. https://doi.org/10.1007/978-1-60327-514-9_16
Download citation
DOI: https://doi.org/10.1007/978-1-60327-514-9_16
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-513-2
Online ISBN: 978-1-60327-514-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)